drugset / Trial / NCT07380659
Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock
Phase 1
Not yet recruiting
18 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.
Timeline
- Start
- 2026-01-20
- Primary completion
- 2027-01-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAP allogeneic immunosuppressive CAR-DC | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | FAP allogeneic immunosuppressive CAR-DC | Cell therapy | 400000 cells/kg | Intravenous |
| Subject | FAP allogeneic immunosuppressive CAR-DC | Cell therapy | 800000 cells/kg | Intravenous |